Literature DB >> 24080661

Pharmacokinetics of hydroxymethylnitrofurazone, a promising new prodrug for Chagas' disease treatment.

Eliana Ometto Pavan Serafim1, Antonio Távora de Albuquerque E Silva, Andréia de Haro Moreno, Ednir de Oliveira Vizioli, Elizabeth Igne Ferreira, Rosângela Gonçalves Peccinini, Maria Lucia Ribeiro, Man Chin Chung.   

Abstract

Hydroxymethylnitrofurazone (NFOH) is a trypanocidal prodrug of nitrofurazone (NF), devoid of mutagenic toxicity. The purpose of this work was to study the chemical conversion of NFOH into NF in sodium acetate buffer (pH 1.2 and 7.4) and in human plasma and to determine preclinical pharmacokinetic parameters in rats. At pH 1.2, the NFOH was totally transformed into NF, the parent drug, after 48 h, while at pH 7.4, after the same period, the hydrolysis rate was 20%. In human plasma, 50% of NFOH was hydrolyzed after 24 h. In the investigation of kinetic disposition, the concentration of drug in serum versus time curve was used to calculate the pharmacokinetic parameters after a single-dose regimen. NFOH showed a time to maximum concentration of drug in serum (Tmax) as 1 h, suggesting faster absorption than NF (4 h). The most important results observed were the volume of distribution (V) of NFOH through the tissues, which showed a rate that is 20-fold higher (337.5 liters/kg of body weight) than that of NF (17.64 liters/kg), and the concentration of NF obtained by in vivo metabolism of NFOH, which was about four times lower (maximum concentration of drug in serum [Cmax] = 0.83 μg/ml; area under the concentration-time curve from 0 to 12 h [AUC0-12] = 5.683 μg/ml · h) than observed for administered NF (Cmax = 2.78 μg/ml; AUC0-12 = 54.49 μg/ml · h). These findings can explain the superior activity and lower toxicity of the prodrug NFOH in relation to its parent drug and confirm NFOH as a promising anti-Chagas' disease drug candidate.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24080661      PMCID: PMC3837917          DOI: 10.1128/AAC.02522-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Bridging studies in clinical development.

Authors:  Jen-pei Liu; Shein-Chung Chow
Journal:  J Biopharm Stat       Date:  2002-08       Impact factor: 1.051

2.  Chagas disease: a new worldwide challenge.

Authors:  José Rodrigues Coura; Pedro Albajar Viñas
Journal:  Nature       Date:  2010-06-24       Impact factor: 49.962

3.  Synthesis and in vitro evaluation of potential antichagasic dipeptide prodrugs of primaquine.

Authors:  M C Chung; M F Gonçalves; W Colli; E I Ferreira; M T Miranda
Journal:  J Pharm Sci       Date:  1997-10       Impact factor: 3.534

4.  Rapid test for the evaluation of the activity of the prodrug hydroxymethylnitrofurazone in the processing of Trypanosoma cruzi messenger RNAs.

Authors:  C F Barbosa; E S Okuda; M C Chung; E I Ferreira; R M B Cicarelli
Journal:  Braz J Med Biol Res       Date:  2007-01       Impact factor: 2.590

Review 5.  Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.

Authors:  Frederik E Stuurman; Bastiaan Nuijen; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2013-06       Impact factor: 6.447

6.  A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.

Authors:  Patricia S Doyle; Chiung-Kuang Chen; Jonathan B Johnston; Stephanie D Hopkins; Siegfried S F Leung; Matthew P Jacobson; Juan C Engel; James H McKerrow; Larissa M Podust
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

7.  Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.

Authors:  Juan C Engel; Kenny K H Ang; Steven Chen; Michelle R Arkin; James H McKerrow; Patricia S Doyle
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

8.  "Subversive" substrates for the enzyme trypanothione disulfide reductase: alternative approach to chemotherapy of Chagas disease.

Authors:  G B Henderson; P Ulrich; A H Fairlamb; I Rosenberg; M Pereira; M Sela; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

9.  Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy.

Authors:  Alvaro Moncayo; Antonio Carlos Silveira
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

10.  Trypanothione reductase from Trypanosoma cruzi. Catalytic properties of the enzyme and inhibition studies with trypanocidal compounds.

Authors:  M C Jockers-Scherübl; R H Schirmer; R L Krauth-Siegel
Journal:  Eur J Biochem       Date:  1989-03-15
View more
  3 in total

1.  Hydroxymethylnitrofurazone treatment in indeterminate form of chronic Chagas disease: Reduced intensity of tissue parasitism and inflammation-A histopathological study.

Authors:  Cauê B Scarim; Cleverton R de Andrade; João A da Rosa; Jean L Dos Santos; Chung M Chin
Journal:  Int J Exp Pathol       Date:  2018-10-15       Impact factor: 1.925

2.  Hepatotoxicity in mice of a novel anti-parasite drug candidate hydroxymethylnitrofurazone: a comparison with Benznidazole.

Authors:  Carolina Davies; Nilay Dey; Olga Sanchez Negrette; Luis Antonio Parada; Miguel A Basombrio; Nisha Jain Garg
Journal:  PLoS Negl Trop Dis       Date:  2014-10-16

Review 3.  Drug/Lead Compound Hydroxymethylation as a Simple Approach to Enhance Pharmacodynamic and Pharmacokinetic Properties.

Authors:  Soraya S Santos; Rodrigo V Gonzaga; Cauê B Scarim; Jeanine Giarolla; Marina C Primi; Chung M Chin; Elizabeth I Ferreira
Journal:  Front Chem       Date:  2022-02-14       Impact factor: 5.221

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.